Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants age is 18 years or older.~2. Participants have a moderate-to-severe rosacea excluding lesions involving the eyes and scalp.~3. Subject must have diagnosed rosacea for at least 6 months prior to screening.~Exclusion Criteria:~1. History of hypersensitivity or allergy to minocycline, any other tetracycline or any other component of the formulation such as Soybean oil or Coconut oil.~2. Women of child bearing potential who are pregnant, lactating (in the last 3 months) or planning to become pregnant during the study period.~3. Moderate or severe rhinophyma, dense telangiectasis (score 3, severe), or plaque- like facial edema.~4. Rosacea conglobata or fulminans, corticosteroid-induced rosacea or isolated pustulosis of the chin, facial erythrosis of known origin other than rosacea (e.g., known carcinoid syndrome).~5. Ocular rosacea (e.g., conjunctivitis, blepharitis, or keratitis) of sufficient severity to require topical ophthalmic or systemic antibiotics, papulopustular rosacea that requires medically indicated systemic treatment.~6. Bacterial folliculitis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FMX-103 1.5% (Type: EXPERIMENTAL): The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied along with vehicle. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
- FMX-103 3% (Type: EXPERIMENTAL): The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied along with vehicle. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
- Vehicle foam (0%) (Type: PLACEBO_COMPARATOR): The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied along with vehicle. The foam will be applied once daily to the face for the 12-week treatment duration of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).